Page 3 - Countries Account News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article ResearchAndMarkets.com s offering. The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase. Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, among others. The n

United statesUnited kingdomEffexor venlafaxineEpidiolex cannabidiolPurdue pharmaEli lilly emgalityRisperdal constaEli lillyInvega sustennaLaura woodAge groupLack of evidenceA new research demonstrates effectiveness of gluconateJanssen pharmaceuticals incAstrazeneca plcTeva pharmaceutical industries ltd